Gilead Sciences, Inc.

NASDAQ:GILD   3:59:59 PM EDT
58.21
-0.32 (-0.55%)
4:59:52 PM EDT: $58.15 -0.06 (-0.10%)
Products, Expansion, Regulatory

HHS Says Gilead Anticipates Producing Sufficient Quantities Of Veklury To Meet Current Needs

Published: 10/01/2020 18:18 GMT
Gilead Sciences Inc (GILD) - Hhs Says Gilead Anticipates Producing Sufficient Quantities of Veklury to Meet Current Needs, Future Demands From Any Waves of Sars-cov-2 Infections.
Hhs Says Cost of Veklury Will Not Change in Transition From U.S. Government Oversight of Allocation to Direct Commercial Sales.
Hhs Says Hospitals Will Continue to Pay No More Than Gilead’s Wholesale Acquisition Price of Veklury, About $3,200 per Treatment Course.
Hhs Says Amerisourcebergen Will Remain Sole Distributor of Veklury Through End of Year to Ensure Consistency & Continuity of Distribution Process.
Hhs Says Federal Government Oversight of the Allocation of Veklury is Not Required Because the Drug is No Longer a Scarce Resource.
Hhs Says Beginning Oct 1, 2020, American Hospitals Can Purchase Veklury (remdesivir) Directly From Drug’s Distributor.
Hhs Says Current Supply of Veklury Exceeds Market Demand As Evidenced by Recent Allocation Numbers From Hhs’ Office of the Aspr.